Adjuvant therapy for premenopausal women with breast cancer: Is it time for another paradigm shift?

Journal of Clinical Oncology

Volumn 20, Issue 24, 2002, Pages 4611-4614

  Pritchard, Kathleen I ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; METHOTREXATE; TAMOXIFEN;

AMENORRHEA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CATHETER ABLATION; EDITORIAL; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; OVARY CYCLE; PREMENOPAUSE; PRIORITY JOURNAL;

EID: 0037115417     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.24.4611     Document Type: Editorial

References (31)

1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2:104-107, 1896
2. Schinzinger A: Ueber carcinoma mammae. Verh Dtsch Ges Chir 18:28-29, 1889
3. Nissen-Meyer R: Ovarian suppression and its supplement by additive hormonal treatment, in Namer M, Lalanne CM (eds): Hormones and Breast Cancer. Paris, France, L'Institut National de la Santé et de la Recherche Médicale, 1975, pp 151-158
4. Meakin JW, Allt WEC, Beale FA, et al: Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 3:45-48, 1983
5. Pritchard KI: Ovarian ablation as adjuvant therapy for premenopausal women with early breast cancer: Phoenix arisen? Lancet 339:95-96, 1992 (editorial)
6. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:71-85, 1992
7. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation in early breast cancer: An overview of the randomized trials. Lancet 348:1189-1196, 1996
8. Davidson N, O'Neill A, Vukov A, et al: Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proc Am Soc Clin Oncol 18:67a, 1999 (abstr 249)
9. Baum M, Rutgers E: Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomized trial by the Cancer Res Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group and the Gruppo Interdisciplinare Valutazione in Interventi in Oncologia. Breast 8:233, 1999
10. Goldhirsch A, Gelber R, Castiglione-Gertsch M: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: The International Breast Cancer Study Group. Ann Oncol 1:183-188, 1990
11. Bianco AR, Del Mastro L, Gallo C, et al: Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 63:799-803, 1991
12. Jonat W: Zoladex versus CMF adjuvant therapy in pre/peri-menopausal breast cancer: Tolerability and amenorrhoea comparisons. Proc Am Soc Clin Oncol 19:87a, 2000 (abstr 333)
13. Richards MA, O'Reilly SM, Howell A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial. J Clin Oncol 8:2032-2039, 1990
14. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
15. Jakesz R, Hausmaninger H, Kubista E, et al: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621-4627, 2002
16. Jonat W, Kaufmann M, Sauerbrei W, et al: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association study. J Clin Oncol 20:4628-4635, 2002
17. Boccardo F, Rubagotti A, Amoroso D, et al: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718-2727, 2000
18. Roche HH, Kerbrat P, Bonneterre J, et al: Complete hormonal, blockade versus chemotherapy in premenopausal early-stage breast cancer patients (pts) with positive hormone-receptor (HR+) and 1-3 node-positive (N+) tumor: Results of the FASG 06 Trial. Proc Am Soc Clin Oncol 19:72a, 2000 (abstr 279)
19. Gelber RD, Goldhirsch A, Castiglione M, et al: Premenopausal oophorectomy versus CMF chemotherapy in stage II breast carcinoma: The International Breast Cancer Study Group (IBCSG). Lancet 342:305, 1993 (letter)
20. Ejlertsen B, Dombernowsky P, Mouridsen HT, et al: Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proc Am Soc Clin Oncol 18:66a, 1999 (abstr 248)
21. Scottish Cancer Trials Breast Group: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Lancet 341:1293-1298, 1993
22. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
23. Bramwell VH, Pritchard KI: Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: Is it standard practice or still a subject for study? Eur J Cancer 35:1625-1627, 1999
24. Henderson IC, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390A)
25. National Institutes of Health Consensus Development Conference Statement: Adjuvant chemotherapy for breast cancer. NIH Consensus Development Statement 5:12, 1985 (letter)
26. Levine MN, Bramwell VH, Pritchard KI, et al: A randomized trial of cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, fluorouracil in premenopausal women with node positive breast cancer. J Clin Oncol 16:2651-2658, 1998
27. Nabholtz J-M, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21:36a, 2002 (abstr 141)
28. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: Five-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602-611, 2001
29. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. J Clin Oncol 14:35-45, 1996
30. Bonneterre J, Roche H, Bremond A, et al: A randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 for node-positive operable breast cancer early report. Proc Am Soc Clin Oncol 15:82a, 1996 (abstr 104)
31. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976